Total
0
Shares
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Trillium Therapeutics (TRIL) has dosed its first patient in Phase 1b study of TTI-622 in combination with carfilzomib and dexamethasone in relapsed/refractory multiple myeloma
  • TTI-622 is a fusion protein that is designed to block the inhibitory activity of CD47, a molecule that is overexpressed by a wide variety of tumours
  • Preclinical studies have shown that TTI-622 exhibits anti-myeloma activity as a monotherapy that is enhanced when combined with proteasome inhibitors
  • Trillium is an immuno-oncology company developing innovative therapies for the treatment of cancer
  • Trillium Therapeutics Inc. (TRIL) is down 5.75 per cent and is trading at USD$8.69 at 3:14 pm ET

Trillium Therapeutics (TRIL) has dosed its first patient in Phase 1b study of TTI-622 in combination with carfilzomib and dexamethasone.

TTI-622 is a fusion protein that is designed to block the inhibitory activity of CD47, a molecule that is overexpressed by a wide variety of tumours.

CD47 binds to SIRPα on macrophages and delivers a “don’t eat me” signal that inhibits the ability of macrophages to engulf and destroy cancer cells.

Preclinical studies have shown that TTI-622 exhibits anti-myeloma activity as a monotherapy that is enhanced when combined with proteasome inhibitors.

“With the dosing of this patient we have begun an exciting new phase of development for TTI-622,” commented Dr. Ingmar Bruns, Trillium’s Chief Medical Officer.

“This is the first patient to receive TTI-622 in combination with another anti-cancer agent, and we are eager to build upon the monotherapy activity that we have observed in multiple hematologic cancers,” added Bruns.

The combination of TTI-622 and carfilzomib plus dexamethasone is being assessed as part of the ongoing, open-label Phase 1a/1b study.

Approximately 30 relapsed/refractory multiple myeloma patients who have received at least 3 prior lines of therapy which must include a proteasome inhibitor, an immunomodulatory drug, and an anti-CD38 antibody will be enrolled.

The primary endpoints are safety and overall response rate.

“Despite the development of new therapeutics and combinations, there remains a significant unmet medical need for myeloma patients who relapse after earlier lines of therapy,” added Dr. Bruns.

“We believe that the combination of TTI-622 and carfilzomib plus dexamethasone has strong potential to address the unmet need and have a significant impact on the myeloma treatment landscape if approved,” concluded Dr. Bruns.

Trillium is an immuno-oncology company developing innovative therapies for the treatment of cancer. 

Trillium Therapeutics Inc. (TRIL) is down 5.75 per cent and is trading at USD$8.69 at 3:14 pm ET.

More From The Market Herald
Theratechnologies - Chief Medical Officer and Senior Vice President Dr. Christian Marsolais

" Theratechnologies (TSX:TH) confirms effectiveness of PDCs against vasculogenic mimicry

Theratechnologies (TH) reports its investigational peptide-drug conjugates (PDCs) are effective in inhibiting vasculogenic mimicry (VM) in ovarian and breast cancer models.

" Algernon Pharmaceuticals (CSE:AGN) receives $2M payment and applies for Nasdaq listing

Algernon Pharmaceuticals (AGN) has recently received a $2M cash payment from a refundable tax credit program for its clinical research work in Australia.

" MediPharm Labs (TSX:LABS) appoints new CEO

 MediPharm Labs (LABS) is pleased to announce that Bryan Howcroft will join MediPharm Labs as Chief Executive Officer and Director, effective November 15,

" Levitee Labs (CSE:LVT) enters into credit facility for up to $12 Million

Levitee Labs Inc. (LVT) has entered into a financing agreement for up to $12 million to fund further business expansion.